During the Microbiome Connect: USA 2022 congress, held last November in Boston, MicrobiomePost discussed with Fabio Grassi, Founder at MV BioTherapeutics SA and Group Leader at Institute for Research in Biomedicine (Bellinzona) about how to optimize existing medicines by examining the latest clinical trials and research into microbiome modulation and response rates and how to understand the mechanisms of action for microbiome contributions to cancer therapeutic response in patients.
Gastroenterology
23 December 2024
